BV in Early Pregnancy: Miscarriage and Preterm Birth Risks

Bacterial vaginosis during the first trimester is one of the most common vaginal infections in pregnancy, and research consistently links it to a higher chance of miscarriage and preterm birth. One cohort study found that women with BV who conceived had roughly double the odds of first-trimester miscarriage compared to women with normal vaginal flora.¹ Yet the relationship between BV and pregnancy outcomes is more tangled than that headline number suggests, and the question of whether treating it actually prevents complications has produced some genuinely surprising answers.

What BV Looks Like in Early Pregnancy

BV is not an infection in the traditional sense. It is a shift in the vaginal microbial community: the protective Lactobacillus species that normally dominate get crowded out by a diverse mix of anaerobic bacteria, most prominently Gardnerella vaginalis and Atopobium vaginae. This shift raises vaginal pH, often produces a thin grayish discharge with a fishy odor, and can be detected on a lab slide by the presence of so-called clue cells. Many pregnant women with BV, though, have no symptoms at all and find out only through routine testing.

During early pregnancy the vaginal microbiome normally becomes less diverse and more heavily colonized by Lactobacillus, a change thought to help protect against ascending infections. When that shift fails to happen, or when a woman enters pregnancy already in a BV state, the result is what researchers classify as Community State Type IV: a vaginal environment dominated by Gardnerella, Atopobium, Prevotella, and other anaerobes rather than Lactobacillus.² That bacterial profile is the starting point for most of the complications BV has been tied to.

The Link to Miscarriage

Several studies have examined whether BV at the start of pregnancy raises miscarriage risk, and the overall picture says yes, though the size of the effect varies. In a British cohort study, about 32% of women with BV who became pregnant miscarried in the first trimester, compared with roughly 19% of women with normal flora. After adjusting for age, smoking, and history of prior miscarriages, the relative risk remained about twofold.³ A separate study looking at women attending their first prenatal visit reported an even stronger association, with a relative risk of about 5.4 for early pregnancy loss in women diagnosed with BV, after accounting for other infections.⁴

Those two numbers differ substantially, which is worth noting. The fivefold figure came from a study that also tested for Mycoplasma and Ureaplasma, and both of those organisms independently raised the risk. BV rarely shows up alone; it tends to involve a whole consortium of bacteria, and disentangling exactly which microbes drive which outcomes is still an active area of research. Another study found that BV was significantly associated with spontaneous abortion overall but appeared to affect second-trimester losses more strongly than first-trimester ones.⁵ The takeaway is not a single clean number, but a consistent direction: BV in early pregnancy raises the chance of pregnancy loss, and the risk probably depends on the specific bacterial mix involved.

How BV May Cause Harm During Pregnancy

The leading theory centers on ascending infection. Normally, the cervical mucus plug and an acidic, Lactobacillus-rich vaginal environment act as barriers to bacteria traveling upward into the uterus. BV weakens both lines of defense: the higher pH and altered mucus make it easier for bacteria to penetrate the cervix.⁶ Once BV-associated organisms reach the uterine lining, they can trigger inflammation that interferes with normal implantation and placental development.

A striking piece of evidence comes from a study that looked at the uterine tissue of women undergoing curettage. Among pregnant women with BV, researchers found a structured Gardnerella biofilm directly attached to the endometrial tissue in five out of eight cases. Women who had a vaginal BV biofilm had about a 50% chance of also having a Gardnerella biofilm inside the uterus. Both pregnancy and BV independently predicted uterine or fallopian tube colonization by these bacteria.⁷ That finding suggests BV is not just a surface-level vaginal issue; the bacteria can physically move upstream.

Animal research reinforces this picture. In a mouse model, Gardnerella vaginalis promoted the vaginal colonization of Group B Streptococcus and enabled it to ascend into the uterus and placenta. Roughly 40% of mice exposed to both organisms developed uterine and placental infection, while none exposed to Group B Strep alone did. The infected placentas showed inflammation and elevated immune signaling molecules on both the maternal and fetal sides.⁸ Although mouse models do not perfectly mirror human pregnancy, the mechanism is biologically plausible and consistent with what clinicians see.

BV and Preterm Birth Risk

The link between BV and preterm birth has been studied even more intensely than its link to miscarriage, and the findings are more nuanced. A case-control study that typed the vaginal microbiome early in pregnancy found that women with a BV-type bacterial community had about four times the odds of early preterm birth (before 34 weeks) compared with women who had a non-Lactobacillus-dominant but non-BV profile. That elevated risk did not hold for late preterm birth (34 to 37 weeks).⁹

A deeper look at specific BV-associated organisms complicates the story. Among all pregnant women in one study, the overall levels of BV-related bacteria were not significantly linked to spontaneous preterm delivery. But among the subset who had already experienced a preterm birth in a prior pregnancy, high levels of certain species before 16 weeks were strongly associated with preterm delivery again, with adjusted odds ratios ranging from about 6 to over 16 depending on the species.¹⁰ In other words, BV in early pregnancy may be most dangerous for women who already have a history of preterm birth, while for first-time mothers with no such history, the risk is less clear.

Screening Recommendations

Given these risks, you might expect universal BV screening in early pregnancy. In fact, the opposite is true. The U.S. Preventive Services Task Force explicitly recommends against screening for BV in pregnant women who are not at increased risk for preterm delivery. For women who are at increased risk (such as those with a prior preterm birth), the Task Force says the evidence is insufficient to determine whether screening and treatment helps or hurts.¹¹

That recommendation might seem counterintuitive when the association data looks so alarming. The reasoning comes down to treatment: if diagnosing BV does not lead to an intervention that reliably improves outcomes, then screening creates anxiety and medical costs without a clear benefit. And that is exactly where the treatment data lands, as the next section explains.

Does Treating BV in Pregnancy Prevent Complications?

Antibiotics clear BV itself very effectively during pregnancy. A Cochrane review pooling ten trials found that antibiotic therapy eradicated BV in the vast majority of cases. But eradicating the infection did not translate into fewer preterm births overall. Across 15 trials involving nearly 6,000 women, treatment showed no significant reduction in preterm delivery before 37 weeks, and no reduction in preterm premature rupture of membranes.¹² A more recent network meta-analysis confirmed this, finding no decrease in preterm delivery, miscarriage, premature rupture of membranes, low birth weight, or NICU admission regardless of the type of antibiotic used.¹³

A large French trial called PREMEVA tested whether systematically screening and treating BV with clindamycin in low-risk pregnancies would reduce late miscarriage or very early preterm birth. It found no benefit at all, and the authors concluded that using antibiotics to prevent preterm delivery in this population “should be reconsidered.”¹⁴

There is one important caveat. The Cochrane review found that when treatment was initiated before 20 weeks of gestation, there was a modest reduction in preterm birth before 37 weeks.¹⁵ That result is based on five trials involving about 2,400 women and suggests timing may matter. Treatment that comes later in pregnancy, after the critical window when ascending infection can set processes in motion, may simply arrive too late. But this early-treatment signal has not been robust enough across different study designs to change mainstream guidelines, which remain cautious.

Why Treatment Does Not Always Work

The disconnect between clearing BV and preventing complications has several possible explanations. One is the biofilm problem. BV-associated bacteria, particularly Gardnerella, form structured biofilms on the vaginal epithelium that are difficult for antibiotics to fully penetrate. Even after clinical signs of BV disappear, remnants of the biofilm can persist and serve as a foothold for the same bacteria to regrow.¹⁶ Recurrence rates for BV after antibiotic treatment are notoriously high, with more than half of treated women experiencing a return of symptoms within months.

Another layer involves which bacteria actually respond to treatment. A study comparing oral and vaginal metronidazole during pregnancy found that concentrations of certain BV-associated species dropped significantly with oral treatment but not vaginal therapy. Meanwhile, the hard-to-kill species designated BVAB3 did not decrease significantly with either route. And Lactobacillus crispatus, one of the protective species you would want to see rebound, did not increase with either treatment.¹⁷ Killing the harmful bacteria without restoring the protective ones leaves the vaginal environment vulnerable to a quick relapse.

The Role of Sexual Partners in Recurrence

For a long time, BV was not considered a sexually transmitted infection, and male partners were not treated. A landmark trial published in the New England Journal of Medicine upended that thinking. The trial was stopped early because the results were so clear: when both the woman and her male partner received antibiotic treatment, BV recurred in 35% of women over 12 weeks. When only the woman was treated, it recurred in 63%.¹⁸ That nearly halved the recurrence rate, strongly suggesting that BV-associated bacteria are passed back and forth between partners.

This finding has direct implications for pregnant women dealing with recurrent BV. If you clear the infection during pregnancy but your partner is still carrying the same organisms, reinfection can happen quickly. Whether partner treatment during pregnancy reduces the risk of adverse pregnancy outcomes has not yet been tested in a dedicated trial, but the biological logic is straightforward: reducing reinfection should reduce the total bacterial burden over the pregnancy.

Who Gets BV and Why

BV is not distributed equally across all populations. In the United States, Black women have significantly higher rates of BV than white women. One study of pregnant women found BV in 64% of Black participants compared with 35% of white participants.¹⁹ That same study found that the disparity tracked closely with differences in chronic stress exposure: Black women in the cohort were far more likely to live in neighborhoods with high rates of violent crime and to report threats to personal safety. Stress is known to alter immune function and hormonal balance, both of which influence the vaginal microbiome. The racial disparity in BV rates is therefore likely a reflection of social and environmental conditions, not innate biological differences.

There is also a genetic dimension. Variants in genes involved in immune recognition, particularly in the Toll-like receptor (TLR) family, appear to influence susceptibility. One study found that about 10% of pregnant women carried a TLR4 variant associated with higher vaginal pH, more than tenfold increases in Gardnerella levels, and elevated inflammatory markers in the vagina.²⁰ Other immune gene variants, particularly in CD14 and TLR1, have been linked to vaginal carriage of Atopobium vaginae during early pregnancy.²¹ These findings help explain why some women seem to develop BV repeatedly despite the same behaviors and exposures as women who never get it. Your immune system’s ability to recognize and respond to BV-associated bacteria is partly hardwired.

Diagnosing BV in Early Pregnancy

In clinical practice, BV is most commonly diagnosed using either the Amsel criteria (a set of four bedside signs including pH, discharge, clue cells, and a “whiff test”) or the Nugent score, which involves scoring a Gram-stained vaginal smear under a microscope. The Nugent score is generally considered the gold standard, but neither method is perfect. One study comparing the two approaches found that only about 75 out of 203 samples from women with Nugent-confirmed BV actually met positive Amsel criteria, meaning the bedside test missed a large proportion of cases.²²

Newer molecular tests using PCR technology are gaining ground. These tests can quantify specific BV-associated bacteria and simultaneously detect Lactobacillus levels, giving a much more detailed picture of the vaginal microbiome. A prospective study testing a real-time PCR panel on over 550 pregnant women between 8 and 12 weeks of gestation found it detected Gardnerella, Prevotella, and Atopobium species more effectively than conventional culture and could determine relative Lactobacillus dominance at the same time.²³ Among the individual organisms tested, Atopobium had the strongest overall diagnostic accuracy for predicting BV when measured by Nugent scoring.²⁴ These molecular approaches are not yet standard of care everywhere, but they represent a more precise alternative to a test that relies on eyeballing bacteria under a microscope.

Probiotics and Emerging Approaches

Given the limitations of antibiotics, there is enormous interest in using probiotics, particularly Lactobacillus strains, to restore or maintain a healthy vaginal microbiome during pregnancy. The results so far are mixed. A small prospective study found that vaginal Lactobacillus casei rhamnosus given to pregnant women who completely lacked vaginal Lactobacillus led to lower Nugent scores and modestly higher gestational ages at delivery compared with untreated women in the same group.²⁵ An exploratory study of oral probiotics (Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14) in pregnant women with BV found that Gardnerella decreased significantly after a month of treatment, with hints that the vaginal microbiome was shifting in a healthier direction.²⁶

But the best-designed trial to date poured cold water on the idea. A double-blind, placebo-controlled trial of oral probiotics during pregnancy found no difference in BV rates between the probiotic and placebo groups at 18 to 20 weeks, no difference in colonization by the probiotic strains, and no detectable effect on the overall vaginal bacterial community.²⁷ The oral route may simply not deliver enough bacteria to the vaginal environment to make a difference. Whether vaginal probiotics perform better in rigorous large trials remains an open question.

BV and IVF

Women undergoing in vitro fertilization face an additional wrinkle. The hormonal stimulation protocols used in IVF cycles appear to disrupt the vaginal microbiome on their own. A pilot study found that controlled ovarian stimulation plus progesterone supplementation reduced the relative proportion of vaginal Lactobacillus and increased pathogenic species including Prevotella. Biodiversity in both the vaginal and endometrial microbiota was greater after stimulation, a pattern that resembles the early stages of BV.²⁸ If you are already prone to BV, the IVF process itself could push the vaginal environment further toward dysbiosis right at the moment you need it to be stable for embryo implantation. This is a young area of research, but it underscores why clinicians increasingly check vaginal health as part of fertility workups.

The Specific Bacteria That Seem to Matter Most

Not all BV is created equal, and one of the more interesting developments in recent years is the realization that specific organisms within the BV consortium may carry different risks during pregnancy. Atopobium vaginae deserves particular attention. It is found in over 95% of women with BV, it plays a key role in building the Gardnerella-dominated biofilm on vaginal tissue, and a Chinese prospective cohort study identified vaginal Atopobium as independently associated with spontaneous abortion in the first trimester.²⁹ The authors proposed that Atopobium’s link to miscarriage may work through BV-related endometritis, where inflammation of the uterine lining interferes with the process that allows an embryo to properly implant and grow.

Meanwhile, species like Leptotrichia, Sneathia, and the fastidious organism designated BVAB1 appear to be especially relevant for preterm delivery risk in women with a history of prior preterm birth.³⁰ The emerging picture is that “BV” is an umbrella term for several distinct microbial configurations, and the clinical consequences may depend heavily on which species happen to dominate. This helps explain why treatment studies have shown such inconsistent results: a one-size-fits-all antibiotic approach treats all BV as the same condition, when the risk profile of each case may vary dramatically based on its bacterial makeup.